E
6.50
-1.10 (-14.47%)
| Previous Close | 7.60 |
| Volume | 410,589 |
| Price / Sales | 2.83 |
| Price / Book | 16.85 |
| 52 Weeks Range |
| Profit Margin | -27.34% |
| Operating Margin (TTM) | -21.71% |
| Diluted EPS (TTM) | -0.840 |
| Quarterly Revenue Growth (YOY) | 7.50% |
| Total Debt/Equity (MRQ) | 367.92% |
| Current Ratio (MRQ) | 2.32 |
| Operating Cash Flow (TTM) | -14.91 M |
| Levered Free Cash Flow (TTM) | -10.11 M |
| Return on Assets (TTM) | -19.21% |
| Return on Equity (TTM) | -117.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Exagen Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -3.2 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.0 |
| Relative Valuation | NA |
| Financial Health | -2.7 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -1.88 |
Select this tab to load the latest available analysis.
|
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 19.82% |
| % Held by Institutions | 45.44% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |